The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
Who’s at the peak? COVID-19 has hit some countries far harder than others, though differences in the way infections are counted locally make it impossible to make a perfect apples-to-apples ...